These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24728665)

  • 1. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.
    Okita K; Izumi N; Matsui O; Tanaka K; Kaneko S; Moriwaki H; Ikeda K; Osaki Y; Numata K; Nakachi K; Kokudo N; Imanaka K; Nishiguchi S; Okusaka T; Nishigaki Y; Shiomi S; Kudo M; Ido K; Karino Y; Hayashi N; Ohashi Y; Makuuchi M; Kumada H;
    J Gastroenterol; 2015 Feb; 50(2):191-202. PubMed ID: 24728665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
    Okita K; Izumi N; Ikeda K; Osaki Y; Numata K; Ikeda M; Kokudo N; Imanaka K; Nishiguchi S; Kondo S; Nishigaki Y; Shiomi S; Ueshima K; Isoda N; Karino Y; Kudo M; Tanaka K; Kaneko S; Moriwaki H; Makuuchi M; Okusaka T; Hayashi N; Ohashi Y; Kumada H;
    J Gastroenterol; 2015 Jun; 50(6):667-74. PubMed ID: 25209978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peretinoin as an adjuvant therapy for hepatocellular carcinoma.
    Tan CK
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1201-1210. PubMed ID: 27649418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma.
    Honda M; Yamashita T; Yamashita T; Arai K; Sakai Y; Sakai A; Nakamura M; Mizukoshi E; Kaneko S
    BMC Cancer; 2013 Apr; 13():191. PubMed ID: 23587162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The acyclic retinoid Peretinoin inhibits hepatitis C virus replication and infectious virus release in vitro.
    Shimakami T; Honda M; Shirasaki T; Takabatake R; Liu F; Murai K; Shiomoto T; Funaki M; Yamane D; Murakami S; Lemon SM; Kaneko S
    Sci Rep; 2014 Apr; 4():4688. PubMed ID: 24732793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
    Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
    Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation.
    Nishikawa H; Osaki Y; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Nasu A; Kita R; Kimura T
    J Clin Gastroenterol; 2013 Apr; 47(4):359-66. PubMed ID: 23090049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma.
    Woo HY; Yoo SY; Heo J
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33435572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
    Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
    Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
    Sansonno D; Lauletta G; Russi S; Conteduca V; Sansonno L; Dammacco F
    Oncologist; 2012; 17(3):359-66. PubMed ID: 22334456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
    Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
    Hepatology; 2006 Dec; 44(6):1543-54. PubMed ID: 17133492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery.
    Kao WY; Su CW; Chau GY; Lui WY; Wu CW; Wu JC
    World J Surg; 2011 Apr; 35(4):858-67. PubMed ID: 21207029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.